Home » Stocks » CMRX

Chimerix, Inc. (CMRX)

Stock Price: $3.62 USD 0.18 (5.23%)
Updated December 4, 4:00 PM EST - Market closed
After-hours: $3.72 +0.10 (2.76%) Dec 4, 7:23 PM

CMRX Stock Price Chart

Key Info

Market Cap 226.73M
Revenue (ttm) 11.02M
Net Income (ttm) -35.35M
Shares Out 62.24M
EPS (ttm) -0.57
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 4
Last Price $3.62
Previous Close $3.44
Change ($) 0.18
Change (%) 5.23%
Day's Open 3.47
Day's Range 3.41 - 3.63
Day's Volume 239,815
52-Week Range 1.27 - 3.81

CMRX Stock News

Seeking Alpha - 3 weeks ago

Chimerix, Inc. (CMRX) CEO Michael Sherman on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 4 weeks ago

DURHAM, N.C., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious disea...

GlobeNewsWire - 1 month ago

DURHAM, N.C., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious disea...

GlobeNewsWire - 2 months ago

DURHAM, N.C., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious di...

Seeking Alpha - 3 months ago

Chimerix, Inc. (CMRX) CEO Mike Sherman on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Chimerix (CMRX) delivered earnings and revenue surprises of 11.11% and 19.83%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 3 months ago

Shares of Chimerix (NASDAQ:CMRX) were flat in pre-market trading after the company reported Q2 results.

GlobeNewsWire - 4 months ago

DURHAM, N.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious dis...

GlobeNewsWire - 5 months ago

Former Eli Lilly Veteran Brings Deep Oncology Clinical and Regulatory Expertise Former Eli Lilly Veteran Brings Deep Oncology Clinical and Regulatory Expertise

Seeking Alpha - 6 months ago

Below is a list of six companies with promising Covid-19 treatments in various stages of development, and the reasons why I have invested in them.

Other stocks mentioned: ATHX, CTSO, CYDY, MESO
Zacks Investment Research - 6 months ago

Chimerix (CMRX) delivered earnings and revenue surprises of -13.33% and -17.27%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 6 months ago

Shares of Chimerix (NASDAQ:CMRX) were unchanged at $2.52 after the company reported Q1 results.

GlobeNewsWire - 7 months ago

FDA Clearance to Proceed with Phase 2/3 Randomized, Double-Blind, Placebo Controlled Study

GlobeNewsWire - 7 months ago

DURHAM, N.C., April 28, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious di...

Zacks Investment Research - 9 months ago

Chimerix (CMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Seeking Alpha - 9 months ago

Chimerix, Inc. (CMRX) CEO Mike Sherman on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 10 months ago

Brincidofovir demonstrated a statistically significant survival advantage in two well-characterized animal models of lethal orthopoxvirus infection Brincidofovir demonstrated a statistically s...

Zacks Investment Research - 11 months ago

Is (CMRX) Outperforming Other Medical Stocks This Year?

GlobeNewsWire - 11 months ago

DURHAM, N.C., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other seri...

Seeking Alpha - 1 year ago

Chimerix's (CMRX) CEO Michael Sherman on Q3 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

Includes All Human Indications Excluding Prevention and Treatment of Smallpox

Zacks Investment Research - 1 year ago

Chimerix (CMRX) delivered earnings and revenue surprises of -105.88% and -37.48%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Chimerix (CMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor Chimerix.

Seeking Alpha - 1 year ago

Chimerix's (CMRX) CEO Mark Iwicki on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Chimerix (CMRX) delivered earnings and revenue surprises of 0.00% and 17.80%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Chimerix (CMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

24/7 Wall Street - 1 year ago

News of changes to its executive team boosted Chimerix Inc. shares on Tuesday. Specifically, the firm announced the appointment of Michael A. Sherman as chief executive of Chimerix, effective ...

About CMRX

Chimerix, a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include dociparstat sodium (DSTAT), a potential first-in-class glycosaminoglycan compound derived from porcine heparin that has low anticoagulant activity but retains the ability to inhibit activities of key proteins implicated in the retention and viability of acute myeloid leukemia blasts and leukemic ste... [Read more...]

Industry
Biotechnology
IPO Date
Apr 11, 2013
CEO
Michael Sherman
Employees
43
Stock Exchange
NASDAQ
Ticker Symbol
CMRX
Full Company Profile

Financial Performance

In 2019, Chimerix's revenue was $12.52 million, an increase of 73.49% compared to the previous year's $7.22 million. Losses were -$112.58 million, 62.0% more than in 2018.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for Chimerix is 6.67, which is an increase of 84.25% from the latest price.

Price Target
$6.67
(84.25% upside)